Roquefort Therapeutics (LON:ROQ) Shares Down 5.9% – Should You Sell?

Roquefort Therapeutics plc (LON:ROQ) shares traded down 5.9% on Wednesday . The stock traded as low as GBX 1.56 ($0.02) and last traded at GBX 1.60 ($0.02). 723,877 shares traded hands during trading, a decline of 72% from the average session volume of 2,583,113 shares. The stock had previously closed at GBX 1.70 ($0.02).

Roquefort Therapeutics Stock Performance

The business’s fifty day simple moving average is GBX 1.75 and its 200-day simple moving average is GBX 3.08. The firm has a market cap of £2.04 million, a P/E ratio of -1.32 and a beta of 0.05. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37.

Roquefort Therapeutics (LON:ROQ) last posted its earnings results on Wednesday, April 30th. The company reported GBX (0.75) (($0.01)) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative return on equity of 29.57% and a negative net margin of 57,057.07%.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.